In December 2023, Medlab Clinical US Inc. and Medlab IP Pty Ltd separated from their parent company, Medlab Clinical LTD, following a shareholder decision. This strategic move allowed founder Dr. Sean Hall to establish Medlab Group Pty Ltd, enabling the free commercialization of its intellectual property.

Dr. Hall and his team bring extensive expertise in human life sciences, having contributed to the success of major pharmaceutical and nutraceutical brands across Australia, New Zealand, the USA, and Europe. As a published author, experienced speaker, and innovative patent creator, Dr. Hall leads Medlab Group’s pursuit of cutting-edge healthcare solutions.

Today, Medlab Group offers a comprehensive range of services and technologies ready for commercial partnerships, including its unique drug delivery platforms and therapeutic innovations, particularly for chronic illnesses. The company’s capabilities extend beyond product development into critical consultancy services that support leadership development, critical thinking, intellectual property generation, product development, clinical trials, chemistry, and reverse engineering. With a global team of experts, Medlab Group collaborates with partners across the nutraceutical and pharmaceutical sectors, covering food supplements, OTCs, OTCRx, and novel therapeutic formulations.